CCK as a treatment for pancreatic acinar cell carcinoma


About this study

The purpose of this study is to learn more about the function of CCK receptor in human ACC cells and test the effect of high concentration CCK on ACC cells.  

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Any adult patients who had diagnosis of ACC and tissue available at Mayo Clinic 
  • Will recruit adult ACC patients who sign the consent form to participate in the study

Control cases

  • Non-ACC patients who have pancreas tissue available including pancreas cystic lesions, chronic pancreatitis, and normal adjacent pancreatic cancer tissue.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Yan Bi, M.D., Ph.D.

Closed for enrollment

Rochester, Minn.

Mayo Clinic principal investigator

Yan Bi, M.D., Ph.D.

Contact us for the latest status

Contact information:

Lizhi Zhang M.D.


More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer